How to set up a psychedelic study: Unique considerations for research involving human participants.
Marcus J. Glennon, Catherine Bird, Prateek Yadav, Patrick Kleine, Shayam Suseelan, Christina Boman-Markaki, Vasileia Kotoula, Matt Butler, Robert Leech, Leor Roseman, David Erritzøe, Deepak P. Srivastava, Celia J. A. Morgan, Christopher Timmermann, Greg Cooper, Jeremy I Skipper, James Rucker, Sunjeev K. Kamboj, Mitul A. Mehta, Ravi Das, Anjali Bhat
Neuroscience & Biobehavioral Reviews July 1, 2026 DOI: 10.1016/j.neubiorev.2026.106657 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Keywords | Ethics Placebo Psychedelics Psychopharmacology Schedule i Subjective experience Therapy |
| Citations | 2 |
| Key findings | The paper provides a formalised, practical guide for setting up psychedelic research studies, addressing unstandardised challenges across sociocultural, political, legal, pharmacological, safety, study design, and experiential domains. |
Abstract
Setting up a psychedelic study can be a long, arduous, and Kafkaesque process. Researchers are faced with a host of challenges in this rapidly evolving field, necessitating a range of considerations that remain largely unstandardised. Many of the complexities inherent to psychedelic research also challenge existing assumptions around, for example, approaches to psychiatric prescribing, the conceptual framing of the placebo effect, and definitions of selfhood. This review paper aims to formalise these unique considerations by addressing the sociocultural, political, legal, pharmacological, safety, study design and experiential facets inherent to a psychedelic study. We bring together several of the major psychedelic research teams across the United Kingdom, identify continuing areas of debate, and provide a practical, comprehensive, experience-based guide, with recommendations for policymakers and future researchers intending to set up a psychedelic research study or clinical trial.
Citations in the library
Cited by 2
Cites 302
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 297 more in the library